最初接受玻璃体内注射贝伐单抗治疗的视网膜中央静脉阻塞患者的预后：长期随访
Outcomes of Patients Initially Treated with Intravitreal Bevacizumab for Central Retinal Vein Occlusion: Long-Term Follow-Up.
作者信息
Bajric Jasmina, Bakri Sophie J
机构信息
a Mayo Clinic Department of Ophthalmology , Rochester , Minnesota , USA.
出版信息
Semin Ophthalmol. 2016;31(6):542-7. doi: 10.3109/08820538.2015.1009555. Epub 2015 Apr 30.
BACKGROUND AND OBJECTIVE
To assess outcomes of visual acuity (VA) and central retinal thickness (RT) in patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO) who were initially treated with bevacizumab and followed for up to four years.
STUDY DESIGN/MATERIALS AND METHODS: In this observational case series, 51 patients with non-ischemic and ischemic CRVO who had initial treatment with bevacizumab were included. Main outcome measures were VA and RT at one year, with follow-up of up to four years.
RESULTS
Mean VA improved from 20/214 at baseline to 20/107 at one year (p = 0.0009) and this improvement was maintained clinically at four years. RT decreased from 595 μm to 339 μm at one year (p = 0.0027) and this was maintained at four years.
CONCLUSION
Patients who received bevacizumab as initial therapy for ME from CRVO maintained VA and RT improvement for up to four years.
背景与目的
评估最初接受贝伐单抗治疗并随访长达四年的视网膜中央静脉阻塞（CRVO）继发黄斑水肿（ME）患者的视力（VA）和视网膜中央厚度（RT）结果。
研究设计/材料与方法：在这个观察性病例系列中，纳入了51例最初接受贝伐单抗治疗的非缺血性和缺血性CRVO患者。主要结局指标为一年时的VA和RT，随访长达四年。
结果
平均视力从基线时的20/214提高到一年时的20/107（p = 0.0009），且这种改善在四年时仍保持临床意义。RT在一年时从595μm降至339μm（p = 0.0027），并在四年时维持这一水平。
结论
接受贝伐单抗作为CRVO继发ME初始治疗的患者，其VA和RT改善可维持长达四年。
Zotero 插件